Results 131 to 140 of about 17,638 (200)

A phase II, multicenter, open-label, single-arm study of berzosertib plus topotecan in patients with relapsed platinum-resistant small-cell lung cancer (DDRiver SCLC 250). [PDF]

ESMO Open
Navarro A, Thomas A, Cheng Y, Chen Y, Reguart N, Yoshida T, Cousin S, Dong X, Yamamoto N, Cappuzzo F, Hallwachs R, Bolleddula J, Sarholz B, Grombacher T, Otte M, Gounaris I, Ferrer J, Moulin C, Paz-Ares L.   +18 more
europepmc   +1 more source

Stability study of topotecan in ophthalmic prefilled syringes for intravitreal delivery. [PDF]

Eur J Hosp Pharm
Bello W, Hosotte C, Stampfli C, Pierrot A, Munier FL, Berger-Gryllaki M, Pezzatti J, Carrez L, Sadeghipour F.   +8 more
europepmc   +1 more source

Role of additional topotecan injections (plus two) in reducing recurrence rate in retinoblastoma of group D and group E patients: a retrospective study. [PDF]

BMJ Open Ophthalmol
Lin X, Zheng Z, Chen H, Qian J, Liu Q, Ma R, Xue K.   +6 more
europepmc   +1 more source

FDA Approval Summary: Tarlatamab for the Treatment of Extensive-Stage Small Cell Lung Cancer. [PDF]

Clin Cancer Res
Liu Y, Nashed J, Barone AK, Yuan M, Amatya AK, Xiang Y, Zhao H, Bi Y, Pegues MA, Miller CP, Lane AR, Mixter BD, Tang S, Pazdur R, de Claro RA, Larkins E.   +15 more
europepmc   +1 more source

HIGH-DOSE INTRAVITREAL TOPOTECAN (100 µ G/0.1 CC) AS MONOTHERAPY FOR RECURRENT/REFRACTORY INTRAOCULAR RETINOBLASTOMA IN SEVEN EYES. [PDF]

Retina
Vempuluru VS, Raval V, Kaliki S.
europepmc   +1 more source

Treatment Sequencing in Platinum-Resistant Epithelial Ovarian Cancer After MIRASOL, KEYNOTE-B96, and ROSELLA. [PDF]

Int J Womens Health
Liu Y, Xu M, Ma J, Zhu Y, Gao M.
europepmc   +1 more source

T-Cell Engagers in Lung Cancer: A Comprehensive Literature Review from Tarlatamab Approval to Next-Generation Strategies. [PDF]

Cancers (Basel)
Saydawi A, Madanieh S, Echeverria SL, Gill A, Modha S, El Emin B, Haider W, Almaalouli B, Shanshal M.   +8 more
europepmc   +1 more source

Reply : Primary suspect drugs of cataracts in pediatric patients: FDA adverse events reporting database analysis. [PDF]

J Cataract Refract Surg
Khan SM, Abboud I, Elhusseiny AM, Elhusseiny AM.   +3 more
europepmc   +1 more source

Comment on: Primary suspect drugs of cataracts in pediatric patients: FDA adverse events reporting database analysis. [PDF]

J Cataract Refract Surg
Rani T, Mandal R, Bandyopadhyay A.
europepmc   +1 more source